Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) has been given an average recommendation of “Hold” by the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $6.00.
A number of brokerages have commented on APTO. ValuEngine raised Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Monday, December 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Aptose Biosciences in a report on Wednesday, December 13th.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down $0.06 on Friday, reaching $3.67. The company’s stock had a trading volume of 417,808 shares, compared to its average volume of 465,442. The company has a market cap of $98.89, a price-to-earnings ratio of -6.12 and a beta of 2.50. Aptose Biosciences has a 1 year low of $0.78 and a 1 year high of $3.97.
An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC raised its position in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the period. Acadian Asset Management LLC owned 0.17% of Aptose Biosciences worth $100,000 as of its most recent filing with the Securities and Exchange Commission. 1.36% of the stock is currently owned by institutional investors and hedge funds.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.